Historical Perspective on Nanoparticles in Imaging from 1895 to 2000

Berezin, Mikhail Y.

doi:10.1002/9781118873151.ch1

Cited by 16 publications

(19 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 123 I-tagged Dg-cSCK demonstrated high labeling efficiency and radiochemical purity that were ratio dependent (Figure 1B) wherein higher Dg-cSCK: 123 I ratios provided greater radiochemical purity, but lower specific activity. The specific activities were consistent with prior NP radiolabeling studies for tumor imaging[52]. The inclusion of the radionuclides provided the ability to radiolabel Dg-cSCKs for quantitative biodistribution and excretion studies in vivo , which are necessary to understand the biologic function of this particular nanomaterial in whole animal models.…”

Section: Resultssupporting

confidence: 71%

In vivo fate tracking of degradable nanoparticles for lung gene transfer using PET and Ĉerenkov imaging

et al. 2016

View full text Add to dashboard Cite

Nanoparticles (NPs) play expanding roles in biomedical applications including imaging and therapy, however, their long-term fate and clearance profiles have yet to be fully characterized in vivo. NP delivery via the airway is particularly challenging, as the clearance may be inefficient and lung immune responses complex. Thus, specific material design is required for cargo delivery and quantitative, noninvasive methods are needed to characterize NP pharmacokinetics. Here, biocompatible poly(acrylamidoethylamine)-b-poly(DL-lactide) block copolymer-based degradable, cationic, shell-cross-linked knedel-like NPs (Dg-cSCKs) were employed to transfect plasmid DNA. Radioactive and optical beacons were attached to monitor biodistribution and imaging. The preferential release of cargo in acidic conditions provided enhanced transfection efficiency compared to non-degradable counterparts. In vivo gene transfer to the lung was correlated with NP pharmacokinetics by radiolabeling Dg-cSCKs and performing quantitative biodistribution with parallel positron emission tomography and Čerenkov imaging. Quantitation of imaging over 14 days corresponded with the pharmacokinetics of NP movement from the lung to gastrointestinal and renal routes, consistent with predicted degradation and excretion. This ability to noninvasively and accurately track NP fate highlights the advantage of incorporating multifunctionality into particle design.

show abstract

Section: Resultssupporting

confidence: 71%

In vivo fate tracking of degradable nanoparticles for lung gene transfer using PET and Ĉerenkov imaging

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Theranostic MNPs normally contain a superparamagnetic iron oxide core, which is used for MRI to detect the tumor, covered by a hydrophilic surface coat on the outside, and have been linked with an anticancer drug or siRNA to treat the tumor. 80 As one of the key examples, Moore and co-workers have reported dextran-coated SPIONs for in vivo siRNA delivery. 11 The amine-dextran coated SPIONs were labelled with Cy5.5 dye for simultaneous optical imaging, and covalently linked to thiolated siRNA duplex and myristoylated polyarginine peptides, which are membrane translocation modules, for intracellular delivery.…”

Section: Theranostic Applications and Pharmacodynamics Of Npsmentioning

confidence: 99%

Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles

et al. 2015

View full text Add to dashboard Cite

Nanoparticles (NPs) are considered a promising tool in both diagnosis and therapeutics. Theranostic NPs possess the combined properties of targeted imaging and drug delivery within a single entity. While the categorization of theranostic NPs is based on their structure and composition, the pharmacokinetics of NPs are significantly influenced by the physicochemical properties of theranostic NPs as well as the routes of administration. Consequently, altered pharmacokinetics modify the pharmacodynamic efficacy and toxicity of NPs. Although theranostic NPs hold great promise in nanomedicine and biomedical applications, a lack of understanding persists on the mechanisms of the biodistribution and adverse effects of NPs. To better understand the diagnostic and therapeutic functions of NPs, this review discusses the factors that influence the pharmacokinetics, pharmacodynamics and toxicology of theranostic NPs, along with several strategies for developing novel diagnostic and therapeutic modalities.

show abstract

“…Similarly, new classes of nanoparticles with tunable properties have been developed for improved targeted treatments, novel imaging modalities, or both at the same time (theranostics). 77 The rise of recombinant technology and nanotechnology thus opened the way for more effective personalized (precision) medicine 78, 79 to diagnose earlier and cure rare genetic diseases and cancers, as well as Alzheimer’s and other diseases.…”

Section: Novel Applications: Biologics Nanotechnology and Imaginmentioning

confidence: 99%

Fluorescence anisotropy (polarization): from drug screening to precision medicine

Zhang

Berezin

2015

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Introduction Fluorescence anisotropy (FA) is one of the major established methods accepted by industry and regulatory agencies for understanding the mechanisms of drug action and selecting drug candidates utilizing a high-throughput format. Areas covered This review covers the basics of FA and complementary methods, such as fluorescence lifetime anisotropy and their roles in the drug discovery process. The authors highlight the factors affecting FA readouts, fluorophore selection, and instrumentation. Furthermore, the authors describe the recent development of a successful, commercially valuable FA assay for Long QT syndrome drug toxicity to illustrate the role that FA can play in the early stages of drug discovery. Expert opinion Despite the success in drug discovery, the FA-based technique experiences competitive pressure from other homogeneous assays. That being said, FA is an established yet rapidly developing technique, recognized by academic institutions, the pharmaceutical industry, and regulatory agencies across the globe. The technical problems encountered in working with small molecules in homogeneous assays are largely solved, and new challenges come from more complex biological molecules and nanoparticles. With that, FA will remain one of the major work-horse techniques leading to precision (personalized) medicine.

show abstract

Historical Perspective on Nanoparticles in Imaging from 1895 to 2000

Cited by 16 publications

References 72 publications

In vivo fate tracking of degradable nanoparticles for lung gene transfer using PET and Ĉerenkov imaging

In vivo fate tracking of degradable nanoparticles for lung gene transfer using PET and Ĉerenkov imaging

Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles

Fluorescence anisotropy (polarization): from drug screening to precision medicine

Contact Info

Product

Resources

About